Search Results - Raymon Niemans
- Showing 1 - 2 results of 2
-
1
Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials by Linda Spiegelberg, Ruud Houben, Raymon Niemans, Dirk de Ruysscher, Ala Yaromina, Jan Theys, Christopher P. Guise, Jeffrey B. Smaill, Adam V. Patterson, Philippe Lambin, Ludwig J. Dubois
Published in Clinical and Translational Radiation Oncology (2019-02-01)Get full text
Article -
2
The Sulfamate Small Molecule CAIX Inhibitor S4 Modulates Doxorubicin Efficacy. by Simon J A van Kuijk, Roben G Gieling, Raymon Niemans, Natasja G Lieuwes, Rianne Biemans, Brian A Telfer, Guido R M M Haenen, Ala Yaromina, Philippe Lambin, Ludwig J Dubois, Kaye J Williams
Published in PLoS ONE (2016-01-01)Get full text
Article